Skip to main content
SpringerLink
Log in

Kontrazeption

Problemfälle

Contraception

Problem cases

  • CME Weiterbildung · Zertifizierte Fortbildung
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Bei der Behandlung mit Ovulationshemmern (OH) treten schwerwiegende Komplikationen wie venöse Thromboembolien, Herzinfarkte und Schlaganfälle nur sehr selten auf. Das Risiko betrifft überwiegend Frauen mit einer Prädisposition oder vorbestehenden Risikofaktoren. Bei gesunden normalgewichtigen Nichtraucherinnen mit unauffälliger Familienanamnese bestehen keine Bedenken gegen die Anwendung von niedrig dosierten Kombinationspräparaten. Für Frauen mit Grunderkrankungen, Risikofaktoren bzw. Kontraindikationen für die Einnahme von OH stehen alternative, sichere kontrazeptive Maßnahmen zur Verfügung.

Abstract

During treatment with ovulation inhibitors, severe adverse effects are very rare, e.g. venous thromboembolism, myocardial infarction, and stroke. The risk increases in women with a predisposition or risk factors. Healthy, nonsmoking females of normal weight and with nonremarkable family history can be treated with low-dose combined hormonal contraceptives, whereas for patients at risk or contraindications for ovulation inhibitors, other safe and reliable contraceptive methods are available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Abou-Setta AM, Al-Inany HG, Farquhar CM (2006) Levonorgestrel-releasing intrauterine device (LNG-IUD) for endometriosis following surgery. Cochrane Database Syst Rev 18(4):CD005072

    Google Scholar 

  2. Aegidius K, Zwart JA, Hagen K et al (2006) Oral contraceptives and increased headache prevalence. The Head-HUNT study. Neurology 66:349–353

    Article  CAS  PubMed  Google Scholar 

  3. Allais G, Castagnoli Gabellari I, Airola G et al (2009) Headache induced by the use of combined oral contraceptives. Neurol Sci 30:S15–S17

    Article  PubMed  Google Scholar 

  4. Allais G, Castagnoli Gabellari I, De Lorenzo C et al (2009) Oral contraceptives in migraine. Expert Rev Neurother 9:381–393

    Article  CAS  PubMed  Google Scholar 

  5. Allen VM, Armson BA, Wilson RD et al (2007) Society of Obstetricians and Gynecologists of Canada. Teratogenicity associated with pre-existing and gestational diabetes. J Obstet Gynaecol Can 29:927–944

    Article  PubMed  Google Scholar 

  6. Anderson GD (2004) Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63(Suppl 4):S3–S8

    CAS  PubMed  Google Scholar 

  7. Archer DF, Kovalevsky G, Ballagh SA, Grubb GS (2009) Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen. Contraception 80:245–253

    Article  CAS  PubMed  Google Scholar 

  8. Berenson AB, Odom SD, Radecki Breitkopf C, Rahman M (2008) Physiologic and psychologic symptoms associated with use of injectable contraception and 20 µg oral pills. AJOG 199:351.e1–351.e12

    Article  CAS  Google Scholar 

  9. Bertoli A, De Pirro R, Fusco A et al (1980) Differences in insulin receptors between men and menstruating women and influence of sex hormones on insulin binding during the menstrual cycle. J Clin Endocrinol Metab 50:246–250

    Article  CAS  PubMed  Google Scholar 

  10. Bragheto AM, Caserta N, Bahamondes L, Petta CA (2007) Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 76:195–199

    Article  CAS  PubMed  Google Scholar 

  11. Brunner LH, Hogue CJ (2005) The role of body weight in oral contraceptive failure: results from the 1995 national survey of family growth. Ann Epidemiol 15:492–499

    Article  PubMed  Google Scholar 

  12. Brunner Huber LR, Hogue CJ (2005) The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at time of conception. Matern Child Health J 9:413–420

    Article  Google Scholar 

  13. Brunner Huber LR, Hogue CJ, Stein AD et al (2006) Body mass index and risk for oral contraceptive failure: a case-control study in South Carolina. Ann Epidemiol 16:637–643

    Article  Google Scholar 

  14. Brunner Huber LH, Toth JL (2007) Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 166:1306–1311

    Article  Google Scholar 

  15. Burkman RT, Fisher AC, Wan GJ et al (2009) Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 79:424–427

    Article  CAS  PubMed  Google Scholar 

  16. Case AM, Reid RL (1998) Effects of the menstrual cycle on medical disorders Arch Intern Med 158:1405–1412

    Google Scholar 

  17. Cole JA, Norman H, Doherty M, Walker AM (2007) Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 109:339–346

    PubMed  Google Scholar 

  18. Curtis KM, Mohllajee AP, Martins SL, Peterson HB (2006) Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 73:179–188

    Article  CAS  PubMed  Google Scholar 

  19. Dinger JC, Cronin M, Möhner S et al (2009) Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 201:263.e1–263.e9

    Article  CAS  PubMed  Google Scholar 

  20. Dutton C, Foldvary-Schaefer N (2008) Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management. Int Rev Neurobiol 83:113–134

    Article  PubMed  Google Scholar 

  21. Endrikat J, Shapiro H, Lukari Lax E et al (2009) A canadian, multicenter study comparing the efficacy of a levonorgestrel-realeasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 31:340–347

    PubMed  Google Scholar 

  22. Etminan M, Takkouche B, Isorna F, Samii A (2005) Risk of ischemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63

    Article  PubMed  Google Scholar 

  23. Farley TMM, Schlesselman JJ, Collins J (1998) Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 57:211–230

    Article  CAS  PubMed  Google Scholar 

  24. Garg SK, Chase HP, Marshall G et al (1994) Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 271:1099–1102

    Article  CAS  PubMed  Google Scholar 

  25. Gerais AS, Rushwan H (1985) A crossover pill study among Sudanese women. Int J Gynaecol Obstet 23:229–233

    Article  CAS  PubMed  Google Scholar 

  26. Godsland IF, Crook D, Simpson R et al (1990) The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 323:1375–1381

    Article  CAS  PubMed  Google Scholar 

  27. Gomes MPV, Deitcher SR (2004) Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 164:1965–1976

    Article  CAS  PubMed  Google Scholar 

  28. Headache Classification Subcommittee of the International Headache Society (HIS) (2004) The International Classification of Headache Disorders (2 nd edn.). Cephalalgia 24:1–151

    Google Scholar 

  29. Hinterholzer S, Riss D, Brustmann H (2007) Symtomatic large bowel endometriosis in a woman with a hormonal intrauterine device: a case report. J Reprod Med 52:1055–1056

    PubMed  Google Scholar 

  30. Holt VL, Cushing-Haugen KL, Daling JR (2002) Body weight and risk of oral contraceptive failure. Obstet Gynecol 99:820–827

    Article  PubMed  Google Scholar 

  31. Holt VL, Scholes D, Wicklund KG et al (2005) Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105:46–52

    PubMed  Google Scholar 

  32. Hubacher D, Lopez L, Steiner MJ, Dorflinger L (2009) Menstrual pattern changes from levonorgestrel subdermal implants and DMPA: systematic review and evidence-based comparisons. Contraception 80:113–118

    Article  CAS  PubMed  Google Scholar 

  33. Kjos SL, Peters RK, Xiang A et al (1998) Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 280:533–538

    Article  CAS  PubMed  Google Scholar 

  34. Klein BE, Klein R, Moss SE (1999) Mortality and hormone-related exposures in women with diabetes. Diabetes Care 22:248–252

    Article  CAS  PubMed  Google Scholar 

  35. Klein BE, Klein R, Moss SE (1999) Exogenous estrogen exposures and changes in diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 22:1984–1987

    Article  CAS  PubMed  Google Scholar 

  36. Kramer HJM, Tolkoff-Rubin NE, Williams WW et al (2003) Reproductive and contraceptive characteristics of premenopausal kidney transplant recepients. Prog Transplant 13:193–196

    Google Scholar 

  37. Lassan-Pezeshki M, Ghazizadeh S, Khatami MR et al (2004) Fertility and contraceptive issues after kidney transplantation in women. Transplant Proc 36:1405–1406

    Article  Google Scholar 

  38. Leguizamon G, Igarzabal ML, Reece FA (2007) Periconceptional care of women with diabetes mellitus. Obstet Gynecol Clin North Am 34:225–239

    Article  PubMed  Google Scholar 

  39. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339:b2890 doi:1136/bmj.b2890

    Article  PubMed  Google Scholar 

  40. Mück A, Neulen J, Thaler C et al (2009) Kontrazeption bei Problemfällen. Ther Umsch 66:117–128

    Article  Google Scholar 

  41. Pack AM, Davies AR, Kritzer J et al (2009) Antiepileptic drugs: are women aware of the interactions with oral contraceptives and potential teratogenicity? Epilepsy Behav 14:640–644

    Article  PubMed  Google Scholar 

  42. Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T (2009) Efficacy of a combined oral contraceptive containing 0,030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0,035 mg ethinylestrdaiol/2 mf cyproterone acetate. Contraception 79:282–289

    Article  CAS  PubMed  Google Scholar 

  43. Parazzini F, di Cintio E, Chatenoud L et al (2000) Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Eur J Obstet Gynecol Reprod Biol 88:11–14

    Article  CAS  PubMed  Google Scholar 

  44. Petersen KR, Skouby SO, Vedel P, Haaber AB (1995) Hormonal contraception in women with IDDM. Influence on glycometabolic control and lipoprotein metabolism. Diabetes Care 18:800–806

    Article  CAS  PubMed  Google Scholar 

  45. Pietrzak B, Bobrowska K, Jabiry-Zieniewicz Z et al (2007) Oral and transdermal hormonal contraception in women after kidney transplantation. Transplant Proc 39:2759–2762

    Article  CAS  PubMed  Google Scholar 

  46. Pomp ER, Rosendaal FR, Doggen CJM (2008) Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 83:97–102

    Article  PubMed  Google Scholar 

  47. Potter L, Oakley D, Wong E, Canamar R (1996) Measuring oral contraceptive pill taking. Fam Plann Perspect 28:154–180

    Article  CAS  PubMed  Google Scholar 

  48. Rimm EB, Manson JE, Stampfer MJ et al (1992) Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35:967–972

    Article  CAS  PubMed  Google Scholar 

  49. Rosenberg MJ, Burnhill MS, Waugh MS et al (1995) Compliance and oral contraceptives: a review. Contraception 52:137–141

    Article  CAS  PubMed  Google Scholar 

  50. Rosendaal FR (1997) Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 78:1–6

    CAS  PubMed  Google Scholar 

  51. Sabers A (2008) Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 17:141–144

    Article  PubMed  Google Scholar 

  52. Shaw RW, Symonds IM, Tamizian O et al (2007) Randomised comparative trial of thermal balloon ablation and levorgestrel intrauterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol 47:335–340

    Article  PubMed  Google Scholar 

  53. St James PJ, Younger MD, Hamilton BD, Waisbren SE (1993) Unplanned pregnancies in young women with diabetes. Analysis of psychosocial factors. Diabetes Care 16:1572–1578

    Article  Google Scholar 

  54. Stringer E, Antonsen E (2008) Hormonal Contraception and HIV disease progression. Clin Infect Dis 47:945

    Article  PubMed  Google Scholar 

  55. Toivonen J, Luukkainen T, Akkonen H (1991) Protective effect of intrauterine release of levonorgetsrel on pelvic infection: three years‘ comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 77:261–264

    Article  CAS  PubMed  Google Scholar 

  56. Trussell J (2007) Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL et al (eds) Contraceptive technology, 19th rev edn. Ardent Media, New York, pp 747–826

  57. Vahratian A, Barber JS, Lawrence JM, Kim C (2009) Family-planning practices among women with diabetes and overweighed and obese women in the 2002 National Survey For Family Growth. Diabetes Care 32:1026–1031

    Article  PubMed  Google Scholar 

  58. Vercellini P, Frontino G, DeGiorgi O et al (2003) Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 80:560–563

    Article  PubMed  Google Scholar 

  59. Vessey M (2001) Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care 27:90–91

    Article  CAS  PubMed  Google Scholar 

  60. Walch K, Unfried G, Huber J et al (2009) Implanon versus medroxyprogesteron acetate: effects on pain scores in patients with symptomatic endometriosis – a pilot study. Contraception 79:29–34

    Article  CAS  PubMed  Google Scholar 

  61. Watkins ML, Rasmussen SA, Honein MA et al (2003) Maternal obesity and risk of birth defects. Pediatrics 111:1152–1158

    PubMed  Google Scholar 

  62. Watts DH, Park JG, Cohn SE et al (2008) Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 77:84–90

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin weist auf folgende Beziehung/en hin: Die Autorin PD Dr. med. Inka Wiegratz ist als Referentin für die Firmen Jenapharm und Bayer Schering Pharma tätig gewesen.

Author information

Authors and Affiliations

  1. Schwerpunkt Gynäkologische Endokrinologie und Reproduktionsmedizin, Klinik für Gynäkologie und Geburtshilfe, Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland

    I. Wiegratz

Authors
  1. I. Wiegratz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Wiegratz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiegratz, I. Kontrazeption. Gynäkologe 42, 949–964 (2009). https://doi.org/10.1007/s00129-009-2487-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-009-2487-7

Schlüsselwörter

Keywords

Search

Navigation